iXCells Biotechnologies and Rosebud Biosciences announced a partnership to combine iXCells’ scalable iPSC platform (iPSCore) with Rosebud’s AI‑driven organoid generation to produce complex 3D human tissue models for rare disease drug discovery and safety testing. The integrated workflow aims to deliver reproducible organoids that capture tissue‑level biology and improve translational predictivity. Steve Smith, CEO of iXCells, said the collaboration expands the company’s end‑to‑end platform and helps predict human‑specific safety and response earlier in development. Rosebud’s CEO Kitch Wilson noted the partnership makes advanced organoid systems more accessible to researchers. Organoids are 3D cellular models that better recapitulate tissue architecture than 2D cultures; their use is growing for toxicity screening and disease modeling where animal models poorly predict human biology.